115
Compiled By: Prince Henry Danquah, Bora Capital Advisors Ltd.
AstraZeneca has become Britain’s first £200bn company following a 20-pc rally in its share price since the start of the year.
Shares in the pharmaceutical business rose 1.1pc yesterday to value the company at £200.3bn.
AstraZeneca’s stock has surged so far this year amid strong sales of its roster of cancer and rare disease medicines.
The drug company jumped ahead of Shell in April to become the most valuable business on the FTSE 100.
AstraZeneca surpassed its long-term revenue targets last year, generating $45.8bn (£35.7bn) of sales compared with $25.7bn in 2014.
Source: newsthemegh.com